Flow-mediated dilatation as a biomarker for cardiovascular risk in hypertension

Journal of Hypertension

Volumn 26, Issue 8, 2008, Pages 1546-1547

  Avolio, Alberto ^a   Grassi, Guido ^b  

^a MACQUARIE UNIVERSITY   (Australia)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR RISK; CORONARY ARTERY BLOOD FLOW; DISEASE MARKER; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HEART HEMODYNAMICS; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; VASODILATATION; BLOOD FLOW; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKER;

BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; REGIONAL BLOOD FLOW; RISK FACTORS; VASODILATION;

EID: 51549109614     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32830b5f50     Document Type: Editorial

References (13)

1. Davis PF. Flow-mediated endothelial mechanotransduction. Physiol Rev 1995; 75:519-560.
2. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:1111-1115.
3. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23:7-17.
4. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23:233-246.
5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007. Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
6. Grassi G, Mancia G. Neurogenic hypertension: is the enigma of its origin near the solution? Hypertension 2004; 43:154-155.
7. Deanfield JE, Halcox JP, RabelinkTJ. Endothelial function and dysfunction. Testing and clinical relevance. Circulation 2007; 115:1285-1295.
8. Anderson TJ. Prognostic significance of brachial flow-mediated vasodilation. Circulation 2007; 115:2373-2375.
9. Muiesan ML, Salvetti M, Paini A, Monteduro C, Galbassini G, Poisa P, et al. Prognostic role of flow-mediated dilatation of the brachial artery in hypertensive patients. J Hypertens 2008; 26:1612-1618.
10. Wilkinson IB, Mohammad NH, Tyrrell S, Hall IR, Webb DJ, Paul VE, et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens 2002; 15:24-30.
11. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
12. McEniery CM, Yasmin, McDonnell B, Munnery M, Wallace SM, Rowe CV, et al. Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial (ACCT II). Hypertension 2008;51:1476-1482.
13. Avolio A. Central aortic blood pressure and cardiovascular risk. A paradigm shift? Hypertension 2008; 51:1470-1471.